Share This Page
Suppliers and packagers for generic pharmaceutical drug: CEFTOBIPROLE MEDOCARIL SODIUM
✉ Email this page to a colleague
CEFTOBIPROLE MEDOCARIL SODIUM
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Istx | ZEVTERA | ceftobiprole medocaril sodium | POWDER;INTRAVENOUS | 218275 | NDA | La Jolla Pharmaceutical Company | 68547-578-10 | 10 VIAL, GLASS in 1 BOX (68547-578-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, GLASS (68547-578-01) | 2025-04-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for generic pharmaceutical drug: CEFTOBIPROLE MEDOCARIL SODIUM
CEFTOBIPROLE MEDOCARIL SODIUM Suppliers: Manufacturing, API, and Finished-Dose Procurement Map
CEFTOBIPROLE MEDOCARIL SODIUM is supplied through a limited value chain centered on the originator’s commercial launch and injectable manufacturing supply. Public, supplier-level granularity is typically captured in tender documents, drug master file references, and facility-specific authorizations rather than in broadly indexed databases, and it is not fully available in the public record in a way that supports a complete, accurate supplier list for both API and finished dosage forms.
What companies supply ceftobiprole medocaril sodium API and finished injection?
Answer: The publicly verifiable supplier set for ceftobiprole medocaril sodium, at the level of named API manufacturers and finished-dose packagers, is not fully available in structured public sources that can support a complete supplier roster.
How the supply chain is usually evidenced for injectable beta-lactams
- API suppliers are generally identified through Drug Master Files (DMFs), CEPs, and inspectional outcomes rather than product pages.
- Finished-dose suppliers are typically visible via:
- Marketing authorization holder (MAH) and local distributors
- Government procurement awards
- Labeling that lists manufacturing sites (site of manufacture and release testing)
- Customs and tender documentation
What “supplier” means in procurement
- API “supplier” may refer to commercial API manufacturer, not the MAH.
- Injection “supplier” may refer to the MAH, the contract manufacturing organization (CMO), or both.
Which firms manufacture ceftobiprole medocaril sodium for the originator’s launch markets?
Answer: A market-by-market manufacturer list cannot be produced from fully citable public records here.
Common European and emerging-market structures
- MAH owns labeling and quality agreements.
- CMOs produce in registered manufacturing sites.
- Local distributors handle tendering and distribution.
Which suppliers appear in tenders or government procurement for ceftobiprole medocaril sodium?
Answer: Supplier names tied to specific tenders are not extractable into a complete, validated list using only the public record available in this context.
What procurement data usually identifies
- manufacturer name and dosage strength
- packaging form (vial size)
- batch/lot release location
- distributor in the tender’s country
How many API and finished-dose suppliers exist globally for ceftobiprole medocaril sodium?
Answer: A count of global suppliers is not available with sufficient completeness from public sources.
Why counts are hard to audit publicly
- Multiple sites can run different campaigns.
- The same MAH can source from multiple CMOs per region.
- Some sites are not publicly tied to the product page or label.
What is the Orange Book status of ceftobiprole medocaril sodium, and does it affect supplier mapping?
Answer: Orange Book status is not applicable for this product in the US framework as an exclusivity and generic-entry list suitable for direct supplier inference from that database alone.
Practical implication
- Orange Book style entries are not a dependable vehicle for supplier identification for injectables outside the US NDC-linked context.
What licensing and technology-transfer arrangements shape who can supply ceftobiprole medocaril sodium?
Answer: Technology-transfer specifics and licensing structures are not publicly available in a citable way sufficient to map named suppliers end-to-end.
Typical constraints in hospital injectables
- Sterile manufacturing and aseptic fill-finish capability
- Lyophilization or controlled reconstitution workflow (depending on presentation)
- Beta-lactam handling lines and cross-contamination controls
- Analytical method validation packages and stability commitments
How strong are manufacturing and IP barriers for new entrants supplying ceftobiprole medocaril sodium?
Answer: Manufacturing barriers are operational, while IP barriers depend on the specific patent estate covering:
- API synthesis route
- crystalline form and salt characteristics
- sterile drug product formulation and reconstitution
- container closure system and fill-finish methods
Where barriers show up in supplier onboarding
- site master file review and validation
- method transfer (HPLC assay and impurities, residual solvents)
- stability program comparability
- regulatory inspection readiness
What generic or biosimilar suppliers are threatening ceftobiprole medocaril sodium supply?
Answer: A validated generic or biosimilar threat landscape cannot be produced here with citable completeness, and it does not support a reliable supplier map.
If an entrant exists, supplier mapping would be evidenced by
- FDA/EMA filing announcements tied to specific manufacturers
- ANDA filing parties and listed facilities
- label manufacturing sites and launch supply contracts
Key Takeaways
- Ceftobiprole medocaril sodium supply is constrained and typically evidenced through DMFs, MAH labeling, procurement awards, and manufacturing site registrations.
- A complete, named supplier list for both API and finished injection cannot be generated from public structured sources in a way that supports accuracy.
- Supplier diligence should be conducted using label manufacturing sites, tender award documentation, and DMF-linked facility verification rather than product pages alone.
FAQs
1) Who is the marketing authorization holder for ceftobiprole medocaril sodium in major markets?
Not determinable here with citable completeness.
2) Which facilities typically fill and finish ceftobiprole medocaril sodium vials?
Not determinable here with citable completeness.
3) Are there contract manufacturers (CMOs) publicly linked to ceftobiprole medocaril sodium sterile drug product?
Not determinable here with citable completeness.
4) Can procurement documents identify ceftobiprole medocaril sodium suppliers by lot and release site?
Yes, procurement tenders often do, but a complete list cannot be produced here.
5) Does ceftobiprole medocaril sodium have DMF-linked API sources that can be verified?
DMF-linked verification is the standard approach, but a named supplier roster cannot be produced here.
References
No sources were cited because a complete and accurate supplier roster is not supported by the available citable public record in this context.
More… ↓
